Below you will find the articles on economics, investing, and finance that we found most interesting for the week.
NB: ($) denotes subscription site.
A last-minute call led to Teva buying Allergan’s generics business, despite months of chasing Mylan.
Biotech high flyers face the gravity test.
The law of unintended consequences rears its head when it comes to “secret” IPO filings. Rather than going public, companies are using the filings to shop themselves to private buyers.
The FT had an in-depth look at prescription painkiller abuse this week.
Can the insurance industry survive driverless cars?
GMO has some interesting commentary on price insensitive buyers and other things that might make one cautious.